NRx is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. NRx recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI™ (Aviptadil), an application for COVID-related respiratory failure (the “NRx COVID-19 Drug”). NRx is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior (the “NRx Antidepressant Drug Regimen”). NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.

NASDAQ: NRXP



Read and review our latest regulatory filings, HERE.

Press Releases

Date
Title
View PDF

May 27, 2021

NRx Pharmaceuticals Names General H.R. McMaster to Company’s Board of Directors

May 26, 2021

NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the CaucasusRegionin Collaboration withthe Lugar Instituteand Cromos Pharma

May 25, 2021

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp

April 28, 2021

NRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

April 26, 2021

Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

April 19, 2021

NRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

April 6, 2021

NRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

March 29, 2021

NRx Announces ZYESAMI™ (aviptadil) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

Feburary 23, 2021

NRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

Feburary 9, 2021

NRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19

Feburary 3, 2021

NRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health

January 11, 2021

NRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (aviptadil) in the I-SPY COVID-19 Trial

NRx Leadership Team

Our leadership is made up of senior pharma executives united in the mission of bringing life-saving treatments to patients.

Jonathan C. Javitt, M.D., M.P.H.

Chief Executive Officer

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.


Robert Besthof, M.I.M.

Head of Operations & Chief Commercial Officer

Read Bio

Robert Besthof, M.I.M.

Head of Operations & Chief Commercial Officer

Mr. Besthof is a global biopharmaceutical executive with a 25+ year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases area, including small as well as billion-dollar brands in Ophthalmology, Neuroscience, Pain, and Pulmonary Vascular Disease. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Band and for various consulting firms. He holds a B.A. from Case Western Reserve University and a master’s in international management from the Thunderbird School of Global Management.

Philip T. Lavin, Ph.D.

Chief Methodologist

Read Bio

Philip T. Lavin, Ph.D.

Chief Methodologist

Dr. Lavin is a highly respected biostatistician with more than 30 years experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics facult at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics in 1983, a company known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 FDA approvals, including 38 PMAs, more to date than any other biostatistician. He has also server as a Special Government Employee for 30 years where he has advised the FDA on complex statistical and policy issues.

Dennis K. McBride, Ph.D.

Chief Strategy Officer & Senior Scientist

Read Bio

Dennis K. McBride, Ph.D.

Chief Strategy Officer & Senior Scientist

Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. He began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories and headquarters organizations, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed the leadership of the Potomac Institute for Policy Studies, which he continues to serve as President Emeritus. Following his ten-year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career there as Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral).

Dennis has served as adviser to Cabinet Secretaries, congressional committees, and to major corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (Flight Surgeon School), the University of Southern California, the London School of Economics, and Harvard Business School, with award of the Ph.D. in experimental psychology, four master’s degrees, and additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely, was elected by faculty in 1999 to full professor, and has served at multiple universities, full- and part-time in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as adjunct Professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.

Wayne Pines

Regulatory & Patient Advocacy Adviser

Read Bio

Wayne Pines

Regulatory & Patient Advocacy Adviser

Mr. Pines previously served as Associate Commissioner of the US Food and Drug Administration.

Harry B. Peled, M.D. FACC, CCS, CCS-P, HEC-C

Clinical Advisor COVID-19

Read Bio

Harry B. Peled, M.D. FACC, CCS, CCS-P, HEC-C

Clinical Advisor COVID-19

Dr. Harry Peled is the Medical director of Cardiology and Critical Care at Saint Jude medical center in Fullerton, California. In addition to being board-certified in cardiology and critical care he is also board-certified in geriatrics, palliative care and Neurocritical care. He graduated from Albert Einstein College of Medicine with special distinction for research. He has authored work published In the New England Journal of Medicine, Chest, Annals of internal medicine, and many others. He also holds a masters in bio ethics and health policy from Loyola University.

Prof. Daniel C. Javitt, M.D., Ph.D.

Co-founder & Chair, Scientific Advisory Board

Read Bio

Prof. Daniel C. Javitt, M.D., Ph.D.

Co-founder & Chair, Scientific Advisory Board

Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuropsychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.

Alessandra Daigneault

General Counsel & Secretary

Read Bio

Alessandra Daigneault

General Counsel & Secretary

Mrs. Daigneault joined NRx as its Corporate Secretary in September 2020. Prior to joining NRx, she was co-founder and Chief Operating Officer of Quantum Governance LLC, where she continues to serve as a director. She also served as Vice President and Chief Legal Counsel for Teligent, Inc. and its successor companies, First Avenue Networks and FiberTower Corporation, all publicly traded telecommunications companies, from October 2000 to May 2008. Ms. Daigneault began her legal career with Milbank LLP and was a Partner at the Washington, D.C. law firm of Tucker, Flyer & Lewis (now Venable LLP) where she represented clients on various corporate and commercial transactions. Ms. Daigneault holds a Bachelor of Science, Magna Cum Laude, from Georgetown University and a Juris Doctor from Georgetown University Law Center.

Randy Guggenheimer

Chief Business Officer

Read Bio

Randy Guggenheimer

Chief Business Officer

Randy brings over 30 years of investment banking experience dedicated to advising biopharmaceutical companies worldwide. He has advised on numerous corporate M&A, partnering transactions and public and private financings. Most recently, Randy was a Managing Director at Young & Partners, a boutique investment banking firm serving the life sciences and chemical industries. Prior to Young & Partners, Randy was Head of Health Care Investment Banking for the Americas at Dresdner Kleinwort Wasserstein and worked for over 15 years at Lehman Brothers as Managing Director in the Healthcare Group, Managing Director in the Mergers and Acquisitions Group and as Co-Head of Healthcare Mergers & Acquisitions.

Randy received an AB degree in Economics at Harvard College and earned an MBA from Harvard Business School.

William V. Fricker

Chief Financial Officer

Read Bio

William V. Fricker

Chief Financial Officer

Mr. Fricker has more than 30 years of pharmaceutical and biotechnology finance experience that includes leadership roles in financial reporting, financial planning & analysis, treasury, and tax. Prior to joining NRx he was Vice President of Finance and Chief Accounting Officer for Immunomedics, Inc. and was instrumental in preparing the Company for commercialization and eventual sale to Gilead. During his career, Mr. Fricker has been responsible for building out finance organizations for both Fortune 100 companies as well as pre-commercial biotech companies. He has held leadership roles at J M Huber Corporation, Tyco International, Johnson & Johnson, and Bristol-Meyers Squibb. He is a Certified Public Accountant and holds a B.S. in Accounting from The Pennsylvania State University together with an MBA from Villanova University.

Jack Hirschfield

Senior Director of Corporate Communications and External Affairs

Read Bio

Jack Hirschfield

Senior Director of Corporate Communications and External Affairs

Jack Hirschfield joined NRx in May 2021 and leads external affairs for NRx.

Prior to joining NRx, Jack was an award-winning broadcast journalist, focusing on politics and healthcare. Jack also served as Director of Communications for Congressman Michael McCaul (TX-10) where he ran media and communication efforts for the Congressman across the globe.

Jack began his healthcare career at Pfizer, serving as Director of Public Affairs and Director of Corporate Affairs. Jack served in a similar position leading U.S. brand communications for oncology neurology at AbbVie, where he was responsible for the communications surrounding multiple launches and managing several campaigns.

Jack holds a Bachelor of Arts from the University of Iowa.

Melvin L. Morganroth, M.D.

Clinical Advisor COVID-19

Read Bio

Melvin L. Morganroth, M.D.

Clinical Advisor COVID-19

Dr. Morganroth received both his undergraduate degree and medical degree from the University of Michigan in Ann Arbor. He is completing both his internship and residency in Internal Medicine at Yale University School of Medicine. He completed a Pulmonary and Critical Care Fellowship at the University of Colorado Health Sciences Center in Denver. He was an Assistant Professor at the University of Michigan in the Pulmonary and Critical Care Division from 1984-1990. At the University of Michigan, in addition to being active in patient care, he was also director of the Critical Care Medicine Unit, co-director of the critical care fellowship training program and carried out basic research on acute lung injury. Since 1990 he has been the director of the research department in the Pulmonary, Critical Care and Sleep Division of The Oregon Clinic. He is active in patient care, teaching and clinical research. He has been the principal investigator in many research studies and authored multiple journal articles and book chapters on topics related to respiratory disease.


Board of Directors

Jonathan C. Javitt, M.D., M.P.H.

Chief Executive Officer

Read Bio

Jonathan C. Javitt, M.D., M.P.H.

Chief Executive Officer

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.

Hon. Sherry A. Glied, Ph.D. Read Bio

Hon. Sherry A. Glied, Ph.D.

 

Dr. Glied, whose principal areas of research are in health policy reform and mental health care policy, was named Dean of New York University’s Robert F. Wagner Graduate School of Public Service in 2013. From 1989-2013, Dr. Glied was professor of health policy and management at Columbia University’s Mailman School of Public Health and served as chair of the department of health policy and management from 1998-2009. In 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She had previously served as senior economist for health care and labor market policy on the President’s Council of Economic Advisers in 1992-1993, under Presidents Bush and Clinton, and participated in the Clinton Health Care Task Force.

Daniel E. Troy, J.D. Read Bio

Daniel E. Troy, J.D.

 

Mr. Troy is Chief Business and Administrative Officer and General Counsel of Valo. Previously, Dan was the General Counsel of GlaxoSmithKline from 2008 until 2018. Previously, he was a partner in the FDA practice at Sidley Austin. In 2001, he was appointed by President Bush to serve as Chief Counsel for the US Food and Drug Administration, where he was a primary liaison to the White House and the US Department of Health and Human Services. From 2006 to 2007, he chaired the American Bar Association’s Section of Administrative Law and was an adjunct scholar at the American Enterprise Institute in Washington, DC.Prior to entering federal service, Dan practiced constitutional, administrative, and appellate law at Wiley Rein and Fielding, served in the Office of Legal Counsel at the US Department of Justice, and clerked for DC Circuit Judge Robert H. Bork. Dan has a JD from Columbia Law School, where he was a Kent and Stone Scholar, and a BS from the Cornell University School of Industrial and Labor Relations. He is the author of numerous publications, and currently chairs the US Litigation Center. In 2013, the Burton Awards named him a “Legend in the Law.”

Hon. LtG. Herbert Raymond McMaster, US Army, Ret.
Chaim Hurvitz Read Bio

Chaim Hurvitz

 

Mr. Chaim Hurvitz has been the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd from April 2002 to 2010 was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.

Patrick Flynn

Audit Committee Chair

Read Bio

Patrick Flynn

Audit Committee Chair

Mr. Flynn is a founding investor in NRx. He is an entrepreneur with more than 30 years of senior executive experience. He has provided leadership to numerous successful organizations and has served in a variety of roles, including CEO, COO, CFO and advisor. Pat currently serves as COO of Good Measures, Inc. He co-founded Predilytics, Inc., which was sold to Welltock, Inc. Previously, Pat served as COO and then as CEO of Health Dialog, which was sold to BUPA International. Pat continued with BUPA, opening their business in the GCC and China. Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management.

Aaron Gorovitz, J.D. Read Bio

Aaron Gorovitz, J.D.

 

Mr. Gorovitz is a partner of the AHG Group. In addition to his 25 years of legal experience in complex commercial transactions, he has considerable involvement in early-stage biotechnology and health information technology companies. Daniel E. Troy, J.D.

Mr. Troy is Chief Business and Administrative Officer and General Counsel of Valo. Previously, Dan was the General Counsel of GlaxoSmithKline from 2008 until 2018. Previously, he was a partner in the FDA practice at Sidley Austin. In 2001, he was appointed by President Bush to serve as Chief Counsel for the US Food and Drug Administration, where he was a primary liaison to the White House and the US Department of Health and Human Services. From 2006 to 2007, he chaired the American Bar Association’s Section of Administrative Law and was an adjunct scholar at the American Enterprise Institute in Washington, DC. Prior to entering federal service, Dan practiced constitutional, administrative, and appellate law at Wiley Rein and Fielding, served in the Office of Legal Counsel at the US Department of Justice, and clerked for DC Circuit Judge Robert H. Bork. Dan has a JD from Columbia Law School, where he was a Kent and Stone Scholar, and a BS from the Cornell University School of Industrial and Labor Relations. He is the author of numerous publications, and currently chairs the US Litigation Center. In 2013, the Burton Awards named him a “Legend in the Law.”

Contact Information

General Inquiries

Phone
+1 484.254.6134

Fax
+1 302.298.0197

Investor Inquiries

Ryan Sheffield
Chief of Staff
NRx, Inc.

Email
rsheffield@nrxpharma.com

Office
+1 484.254.6134, ext. 723

Media Inquiries

Jack Hirschfield
Sr. Director, External Affairs Lead
NRx, Inc.

Email
jhirschfield@nrxpharma.com

Office
+1 512.674.5163